Phase 2 N=93 A Study of Cariprazine in Patients With Chronic Stable Schizophrenia
Schizophrenia
Primary: Change From Baseline to Week 48 in the PANSS Total Score — -38.5 Units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=125 A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia
Schizophrenia
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 78; 42 Participants
Phase 3 N=386 To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012)(COMPLETED)(P05770)
Schizophrenia
Primary: Time to Relapse or an Impending Relapse — 0; 3; 1; 14 relapses
Phase 3 N=187 Long-Term Efficacy and Safety of Asenapine Using Haloperidol as a Positive Control (41513)(COMPLETED)(P05785)
Schizophrenia
Primary: Loss of Effect Over Time — 7; 15; 6; 3 Participants
Phase 3 N=305 A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.
Schizophrenia
Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Study Discontinuation — 153; 77; 16; 0 Participants
Phase 3 N=282 A Long-term Trial of OPC-34712 in Patients With Schizophrenia
Schizophrenia
Primary: Percentage of Participants With Adverse Events — 156; 79; 95; 38 Participants
Phase 3 N=752 Long-term Study of Cariprazine in Patients With Schizophrenia
Schizophrenia
Primary: Change From Baseline to Week 48 in the PANSS Total Score — 66.5; -5.0 Units on a scale
Phase 3 N=200 Long-term Study of DSP-5423P in Patients With Schizophrenia
Schizophrenia
Primary: Adverse Events and Adverse Drug Reactions, Etc. — 82; 92; 174; 60 Participants
Phase 3 N=248 Long-Term Study of MP-214 in Patients With Schizophrenia
Schizophrenia
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 67; 92; 50 Participants
Phase 3 N=228 A Long-Term Study of JNS007ER in Patients With Schizophrenia
Schizophrenia
Primary: Incidence of Adverse Events — 97.4 percentage of patients
Phase 2 N=61 A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia
Schizophrenia
Primary: Number of Subjects With an Adverse Events in a One Year Open Label Lurasidone Study — 59 participants
Phase 3 N=500 Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia
Schizophrenia
Primary: Participants With Treatment-Emergent Adverse Events (TEAE) — 306; 21; 22; 18 Participants
Phase 3 N=42 A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia
Schizophrenia
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 42 Participants
Phase 3 N=478 A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
Schizophrenia
Primary: Number of Subjects With Treatment-emergent Adverse Events (TEAEs) — 51; 190 participants
Phase 3 N=292 Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia
Chronic Schizophrenia
Primary: Relapse of Psychotic Symptoms — 29; 21 participants
Phase 3 N=239 Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia
Schizophrenia
Primary: Percentage of Participants With Adverse Events (AEs) — 60.2; 56.4; 65.2; 60.5 percentage of participants
Phase 4 N=450 15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
Schizophrenia
Primary: Time to First Treatment Failure — 416; 226 Days
Phase 3 N=265 A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
Schizophrenia
Primary: Number of Subjects With Adverse Events — 161; 93; 61; 7 Participants
Phase 4 N=133 Paliperidone Extended Release in Schizophrenia Participants With Duration of Illness Less Than 10 Years
Schizophrenia
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) - Total Score at Week 13 — 88.98; 22.468 units on a scale
Phase 3 N=277 A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
Schizophrenia
Primary: Number of Participants With Adverse Events (AEs) — 136 Participants
N/A N=14 First Episode Schizophrenia and Cannabis-Related Disorder Study
Cannabis-Related Disorder · Substance-Related Disorders · Schizophrenia
Primary: Number of Participants Demonstrating Improvement in Substance Use — 3; 3 participants
Phase 3 N=523 Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831
Schizophrenia · Schizophreniform Disorder · Bipolar I Disorder
Primary: Incidence of Adverse Events — 314 Participants
N/A N=88 Cognitive-Behavioral Therapy in Veterans With Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Changes in Positive Schizophrenia Symptoms — 3.21; 3.30; 3.04; 2.89 units on a scale — p=.30
Phase 4 N=40 An Efficacy and Safety Study of Long-Term Risperidone Microspheres in Participants With Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Change From Baseline in Total Positive and Negative Syndrome Scale (PANSS) Score at Week 96 — 73.00; 18.24 Units on a scale
N/A N=39 Anti-Inflammatory Treatment of Schizophrenia
Schizophrenia
Primary: Change in Persistent Positive Symptoms — 13; 14; 14; 14 units on a scale
Phase 3 N=629 Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Number of Participants With Adverse Events. — 395; 189 participants
Phase 3 N=157 Long-term Study of Asenapine in Participants With Residual Subtype, Receiving Multiple or/and High Dose Drugs, or Treatment Refractory Schizophrenia (P06238)
Schizophrenia
Primary: Change From Baseline in Weight at Week 52 — 0.25 kg
Phase 2 N=41 Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Verbal Short Term Memory — 43.7; 37.9; 43.6; 40.8 t-score — p=0.90
Phase 2 N=98 Safety and Tolerability Study of Drug to Treat Schizophrenia
Schizophrenia
Primary: Number of Participants With Adverse Events — 19; 22; 18 participants
Phase 4 N=31 Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual
Schizophrenia · Dual Diagnosis · Schizoaffective Disorder
Primary: Average Over Time of Intensity of Cannabis Use (Used to Evaluate Treatment Efficacy) — 0.02; 4.56 Joints per week — p=.088